RATIONALE: Collecting and storing samples of bone marrow and blood from patients with cancer to study in the laboratory may help doctors find better ways to treat the cancer. PURPOSE: This research study is looking at natural killer cells in bone marrow and blood samples from patients with hematologic cancer and from patients who do not have cancer.
OBJECTIVES: * To collect normal and malignant cells in bone marrow and peripheral blood samples from patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or multiple myeloma and from patients with no malignancy to use as target cells in cytotoxicity assays. * To collect information about HLA type and immunophenotype of malignant cells as determined by clinical flow cytometry. OUTLINE: Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing. Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.
Study Type
OBSERVATIONAL
Enrollment
34
All specimens will be collected using the Pathology Residual Tissue Procurement.
Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.
Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
Collection of normal and malignant cells to use as target cells in cytotoxicity assays
Time frame: We anticipate collecting approximately 30 samples in total, over a 1-2 year period.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.